Rachel McMinn bought $969k of NGNE
Chief Executive Officer at Neurogene Inc.. 47,500 shares at an average of $20.40, traded Nov 22, 2024, filed Nov 25, 2024.
Score components
- +25RoleCEO
- +25Trade size$969k at market
- 0Relative to holdingsHoldings up 3.8%
- 0Price contextNo price history yet
- +15Cluster3 insiders buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m +1.4%, 3m -25.6%, 6m -22.6%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001404644-24-000112, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Nov 22, 2024 | POpen-market purchase Common Stock | +47,500 | $20.40 | $969k | 1,297,859 | Nov 25, 2024 |
Related signals
Other insiders at Neurogene Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 13Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $173k 4,800 shares | -5% | |
| 13Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $167k 4,800 shares | -5% | |
| 16Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $300k 9,600 shares | -9% | |
| 24Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $55k 2,558 shares | -2% | |
| 10Weak | Neurogene Inc. | Julie Jordan Chief Medical Officer | $18k 828 shares | -6% | |
| 28Weak | Neurogene Inc. | Rachel McMinn Chief Executive Officer | $74k 3,352 shares | -0% | |
| 26Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $141k 6,797 shares | -18% | |
| 26Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $84k 4,045 shares | -4% | |
| 20Weak | Neurogene Inc. | Christine Mikail Cvijic President and CFO | $121k 4,800 shares | -4% | |
| 10Weak | Neurogene Inc. | Stuart Cobb Chief Scientific Officer | $103k 6,797 shares | -25% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.